Austin-based Ambion Inc. has sold its research division, the bulk of the company,to Norwalk, Conn.- based Applera Corp. for $273 million in cash. Applera's Applied Biosystems Group will run Ambion, which had $52 million in 2005 revenue. CEO Matt Winkler (the new multimillionare of Austin TX), plans now to take Ambion's remaining 100 employees to spin off the company's $5 million diagnostic unit. That company, which will be called Asuragen, will develop cancer based molecular diagnostic tests.
Ambion acquired for $273 million
BioBOOM Op/Ed: Well the rumors seem to be true. Nice move by the wizard of RNA. Winkler gets a huge cash infusion into his future efforts in MDX and ABI gains one great brand name for RNA research tools. Only 2 questions remain: will ABI protect the brand or ruin it, time will tell and will micro-rna be big for diagnostics (We think YES). Know this, there were many players looking at this opportunity including Invitrogen, Qiagen, Eppendorf, Sigma and others. But looks like ABI pulled the trigger and came in closest to the $300mil asking price.
- ► 2013 (23)
- ► 2008 (24)
- ► 2007 (65)
- ► 2006 (77)
- Tiny biosensor to detect cancer
- Ambion acquired for $273 million
- Gene therapy may cure 2 blood diseases
- Deadly fungus gene code cracked
- Signs that the H5N1 bird flu virus may be developi...
- Why biotechs are good bet for 2006
- Mining biotech's data mother lode
- Seoul University Probes Stem Cell Research
- NIH Uses Live Viruses for Bird Flu Vaccine
- Experts to Create Genetic Map of Cancer
- Mice Created With Human Brain Cells
- Cancer as a Scout and Recon team working for it - ...
- Study says farmers benefiting from higher yields, ...
- Gates puts money where mouth is and that might jus...
- Thousands of Babies Have Strokes Annually
- Swedish HIV vaccine revives hopes for DNA path
- Bird by Bird, China Tackles Vast Flu Task
- A total of 386 presumptively viremic blood donor...
- ▼ December (18)